en
This whitepaper provides a comprehensive analysis of the polymorph patent landscape for the 46 new drugs approved by the FDA in 2025, with a specific focus on the 30 small molecule new molecular entities. By examining the administration routes and dosage forms, the report identifies 27 solid and semi-solid preparations, revealing that 81.5% of these products have established polymorph patent strategies—a testament to the critical importance of solid-state IP strategies.
Subscribe to be the first to get the updates!
